ClinicalTrials.gg
Active, not recruitingNCT05889117Updated Sep 30, 2025

Brain Stimulation for Concussion

An interventional study of Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure) in Transcranial Magnetic Stimulation, Magnetic Resonance Imaging and Neuropsychological Tests, sponsored by The Mind Research Network. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Primary conditionPost-Concussion SyndromeRegistry: Brain Injuries, TraumaticReclassifiedWhy we changed it
Registry
Brain Injuries, Traumatic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Concussion Syndrome
Why
  1. The study's listed conditions name Post-Concussion Syndrome, a narrower term within Brain Injuries, Traumatic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Mind Research Network · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.

Planned enrollment
49th of 61
15 · median 40
Started
2023
with 2 others
No phase
35 of 77
6 open now
Primary completion
2025-04
later than 2 of 19 live
Registered
62nd of 77
by date

Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 49th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2023, is one of 35 with no phase, reaches primary completion later than 2 of the 19 other live ones, and was the 62nd registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Post-Concussion Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a new type of magnetic brain stimulation in patients with persistent post-concussive symptoms. Participants will undergo detailed MRI scans before and after 30 treatment sessions (of 3-10 minutes each). The main questions the study aims to answer are:

  • Will this new type of treatment result in fewer symptoms and better daily functioning?
  • What are the effects of this treatment on brain functioning?
Read the detailed description

Repetitive transcranial magnetic stimulation (rTMS) seems a promising treatment option for patients with persistent post-concussive symptoms (PPCS). Traditional rTMS sessions are relatively long in duration and can be exhaustive for patients with PPCS. Intermittent theta-burst stimulation (iTBS) is a newer and more rapid form of rTMS, which only takes up to 10 minutes per session. However, little is known about the effects of iTBS in patients with PPCS. Furthermore, there is a pressing need for methods that reliably measure the effects of TMS treatments in-vivo. Using diffusion magnetic resonance spectroscopy (dMRS) changes in neural and glial cell morphology can be quantified, which makes it possible to disentangle neurometabolic changes related to neural injury and neuroinflammation, two key elements in the pathophysiology of mTBI.

In the current study, 15 patients with chronic (>3 months after mTBI) PPCS will undergo a total of 30 iTBS sessions. After a baseline scan, patients will enter a 2-week control waitlist period. Following the waitlist control, a pre-treatment scan is acquired, followed by the stimulation sessions, and final post-treatment scan. The scanning protocol includes T1 and T2 imaging, dMRS, multi-shell diffusion MRI (dMRI), as well as a demanding executive function fMRI task, and resting-state fMRI (rs-fMRI). A comprehensive battery of clinical tests will be administered at all time points, which includes cognitive testing, self-report of symptoms and emotional distress. Long-term outcome is determined three months after start of the study.

Specific study aims are:

Aim 1: To determine the effects of a precision-medicine iTBS guided approach applied to the left dorsolateral prefrontal cortex (DLPFC) on clinical recovery in patients with PPCS relative to waitlist control.

Aim 2: To determine the neurometabolic effects of iTBS in both the left and right DLPFC as measured with dMRS in patients with PPS, and to untangle differential effects on pathophysiological processes (e.g., neural plasticity vs. anti-inflammatory effects).

Aim 3: To determine the relationship of these neurometabolic effects and the integrity of major frontoparietal white matter tracts (as measured with dMRI), as well as activation and functional connectivity of key large-scale cognitive and emotional networks (i.e., executive, default mode, and salience network), measured using task-based and resting-state fMRI.

03

Conditions studied

  • Transcranial Magnetic Stimulation
  • Magnetic Resonance Imaging
  • Neuropsychological Tests
  • Traumatic Brain Injury
  • Post-Concussion Syndrome

Browse trials for

Keywords

  • Transcranial Magnetic Stimulation
  • Magnetic Resonance Imaging
  • Neuropsychological Tests
  • Traumatic Brain Injury
  • Post-Concussion Syndrome
  • TMS
  • Theta-burst
  • Diffusion magnetic resonance spectroscopy
04

In context

Post-Concussion Syndrome Reclassified

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

This study's planned enrollment of 15 is below the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.

Browse Post-Concussion Syndrome studies →

Lead sponsor

The Mind Research Network is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Compared within Post-Concussion Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Injuries, Traumatic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult age at inclusion 18-64 years.
  • mTBI as defined by an altered mental status at time of injury, and LOC of max 30 min, GCS 13-15 (after 30 min), and PTA max 24 hrs.
  • Persistent post-traumatic symptoms in chronic phase (>3 months post-injury).

Exclusion criteria

Exclusion Criteria:

  • History of developmental, neurological (e.g., epilepsy) or serious mental health disorders (e.g., schizophrenia, bipolar disorder) prior to TBI onset.
  • History of a previous substance use disorder except for alcohol, or a currently active substance use disorder (within last 6 months.)
  • for MRI (e.g., any implanted ferromagnetic materials, claustrophobia, pregnancy) or iTBS (e.g., history of seizures).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Waitlist-control-treatment-group

    After a 2-week control waitlist period, patient receive 30 treatments.

    Device: Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure)

Interventions

  • DeviceIntermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure)

    3-10 minute sessions of brain stimulation applied to the left dorsolateral prefrontal cortex, up to 10 sessions a day, 30 sessions in total, planned within 2 weeks.

    Also known as: transcranial magnetic stimulation (TMS)

07

What researchers measure

Primary outcomes

  1. Post-concussive symptoms

    Rivermead post concussion symptoms questionnaire (16 items, rated 0-4, higher number indicating more symptoms, max score of 64; decrease of the score means improvement of symptoms)

    Time frame: Post-treatment (after completion of all sessions, at ~4 weeks), and at 3 months after start of the study for the individual participant. Data will be reported at the conclusion of the study for all participants.

  2. Neurometabolite diffusion related to neuronal function and inflammation

    As measured with diffusion MRS (diffusion of neurometabolites computed as the apparent diffusion coefficient (ADC)).

    Time frame: Post-treatment for the individual participant (~4 weeks). Data will be reported at the conclusion of the study for all participants.

Secondary outcomes

  1. Cognitive functioning

    Neuropsychological test scores (attention measured using Stroop interference test: T scores, 0-100, higher scores indicating better performance; processing speed measured using the Symbol search test, also T-scores). Increase in score means clinical improvement.

    Time frame: Post-treatment for the individual participant (~4 weeks). Data will be reported at the conclusion of the study for all participants.

  2. Functional outcome

    Glasgow Outcome Scale Extended (range 1-8, 1=dead, 8=complete recovery; increase in score means clinical improvement).

    Time frame: At 3 months after start of the study for the individual participant. Data will be reported at the conclusion of the study for all participants.

  3. Brain network functioning

    As measured with advanced MRI (e.g., improvement on the multimodal attention task can be reflected by a change in percent signal change in the dorsolateral prefrontal cortices of the executive network, which can be either an increase or decrease).

    Time frame: Post-treatment for the individual participant (~ 4 weeks). Data will be reported at the conclusion of the study for all participants.

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Yes — Demographic, clinical, structural MRI, functional MRI, diffusion MRI, and diffusion MRS data will de-identified, linked to a global unique identifier (GUID) and uploaded to The Federal Interagency Traumatic Brain Injury Research (FITBIR) system. These data will be collected on 15 patients with mild traumatic brain injury. All data are exported in industry-specific, but standardized, formats to promote future research endeavors based on FAIR (Findable, Accessible, Interoperable, and Reusable) Data Principles.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2025, 17 months.

Of 54 non-industry interventional studies with no phase under Post-Concussion Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's 17 months is below that.

Counting every sponsor, half of 56 studies reached it within 40 months; a quarter within 23 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
Jun 5, 2023
StartActual
Oct 30, 2023
Primary completionActual
Apr 1, 2025
CompletionEst.
May 2026
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05889117
Lead sponsor
The Mind Research Network
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Oct 30, 2023
Primary completion
Apr 1, 2025
Completion
May 2026 (estimated)
Last update
Sep 30, 2025

Study contacts

Harm J van der Horn, MD PhD
principal investigator · Mind Research Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion